Page 38 - AN-1-1

Advanced Neurology Gastrointestinal symptoms in PD

70. Sakakibara R, Doi H, Sato M, et al., 2015, Nizatidine 81. West CL, Mao YK, Delungahawatta T, et al., 2020,
ameliorates slow transit constipation in Parkinson’s disease. Squalamine restores the function of the enteric nervous
J Am Geriatr Soc., 63(2): 399–401. system in mouse models of Parkinson’s disease. J Parkinsons
Dis, 10(4): 1477–1491.
https://doi.org/10.1111/jgs.13279
https://doi.org/10.3233/JPD-202076
71. Sun WM, Hasler WL, Lien HC, et al., 2001, Nizatidine
enhances the gastrocolonic response and the colonic 82. Albanese A, Brisinda G, Bentivoglio AR, et al., 2003,
peristaltic reflex in humans. J. Pharmacol. Exp. Ther, 299(1): Treatment of outlet obstruction constipation in Parkinson’s
159–163. disease with botulinum neurotoxin A. Am J Gastroenterol,
98(6): 1439–1440.
72. Ondo WG, Kenney C, Sullivan K, et al., 2012, Placebo-
controlled trial of lubiprostone for constipation associated https://doi.org/10.1111/j.1572-0241.2003.07514.x
with Parkinson disease. Neurology, 78(21): 1650–1654. 83. Jost WH, Schimrigk K, 1993, Cisapride treatment of
https://doi.org/10.1212/WNL.0b013e3182574f28 constipation in Parkinson’s disease. Movement Disord, 8(3):
339–343.
73. Kuai XY, Yao XH, Xu LJ, et al., 2021, Evaluation of fecal
microbiota transplantation in Parkinson’s disease patients 84. Sakakibara R, Odaka T, Lui Z, et al., 2005, Dietary
with constipation. Microb Cell Fact, 20(1): 98. herb extract dai-kenchu-to ameliorates constipation in
parkinsonian patients (Parkinson’s disease and multiple
https://doi.org/10.1186/s12934-021-01589-0 system atrophy). Movement Disord, 20(2): 261–262.
74. Cadeddu F, Bentivoglio AR, Brandara F, et al., 2005, https://doi.org/10.1002/mds.20352
Outlet type constipation in Parkinson’s disease: Results of
botulinum toxin treatment. Aliment Pharmacol Ther, 22(10): 85. Karasawa H, Pietra C, Giuliano C, et al., 2014, New
997–1003. ghrelin agonist, HM01 alleviates constipation and
L-dopa-delayed gastric emptying in 6-hydroxydopamine
https://doi.org/10.1111/j.1365-2036.2005.02669.x rat model of Parkinson’s disease. Neurogastroenterol
75. Morgan JC, Sethi KD, 2007, Tegaserod in constipation Motil, 26(12): 1771–1782.
associated with Parkinson disease. Clin Neuropharmacol, https://doi.org/10.1111/nmo.12459
30(1): 52–54.
86. Gourcerol G, Maltete D, Chastan N, et al., 2019, Does
https://doi.org/10.1097/01.WNF.0000240942.21499.97 bilateral deep brain stimulation of the subthalamic nucleus
76. Zangaglia R, Martignoni E, Glorioso M, et al., 2007, modify ano-rectal motility in Parkinson’s disease? Results
Macrogol for the treatment of constipation in Parkinson’s of a randomized cross-over study. Neuromodulation, 22(4):
disease. A randomized placebo-controlled study. Movement 478–483.
Disord, 22(9): 1239–1244. https://doi.org/10.1111/ner.12947
https://doi.org/10.1002/mds.21243 87. Liu Z, Sakakibara R, Odaka T, et al., 2005, Mosapride
77. Sullivan KL, Staffetti JF, Hauser RA, et al., 2006, Tegaserod citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist,
(Zelnorm) for the treatment of constipation in Parkinson’s ameliorates constipation in parkinsonian patients.
disease. Movement Disord, 21(1): 115–116. Movement Disord, 20(6): 680–686.
https://doi.org/10.1002/mds.20666 https://doi.org/10.1002/mds.20387
78. Chiu CM, Wang CP, Sung WH, et al., 2009, Functional 88. Kola S, Prichard DO, Bharucha AE, et al., 2021, A prospective
magnetic stimulation in constipation associated with pilot study of the effects of deep brain stimulation on
Parkinson’s disease. J Rehabil Med, 41(13): 1085–1089. olfaction and constipation in Parkinson’s disease. Clin
https://doi.org/10.2340/16501977-0456 Neurol Neurosurg, 207: 106774.
79. McClurg D, Hagen S, Jamieson K, et al., 2016, Abdominal https://doi.org/10.1016/j.clineuro.2021.106774
massage for the alleviation of symptoms of constipation 89. Chua KK, Wong A, Chan KW, et al., 2017, A randomized
in people with Parkinson’s: A randomised controlled pilot controlled trial of chinese medicine on nonmotor symptoms
study. Age Ageing, 45(2): 299–303. in Parkinson’s disease. Parkinsons Dis, 2017: 1902708.
https://doi.org/10.1093/ageing/afw005 https://doi.org/10.1155/2017/1902708
80. Tateno F, Sakakibara R, Yokoi Y, et al., 2011, Levodopa 90. McClurg D, Walker K, Aitchison P, et al., 2016, Abdominal
ameliorated anorectal constipation in de novo Parkinson’s massage for the relief of constipation in people with
disease: The QL-GAT study. Parkinsonism Relat Disord., Parkinson’s: A qualitative study. Parkinsons Dis,
17(9): 662–666. 2016: 4842090.
https://doi.org/10.1016/j.parkreldis.2011.06.002 https://doi.org/10.1155/2016/4842090

Volume 1 Issue 1 (2022) 14 https://doi.org/10.36922/an.v1i1.9